- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05064852
A Real-world Study of the Safety and Efficacy of Surufatinib in the Treatment of Biliary Tract Carcinoma
September 22, 2021 updated by: Qilu Hospital of Shandong University
This is a prospective, single-arm, open-label,multi-center, observational real-world clinical study to observe and evaluate the efficacy and safety of Surufatinib in the treatment of patients with biliary tract cancer (BTC).
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
This is a prospective, single-arm, open-label,multi-center, observational real-world clinical study to observe and evaluate the efficacy and safety of Surufatinib in the treatment of patients with biliary tract cancer (BTC).
About 200 subjects are prepared to recruit in the study.
Study Type
Observational
Enrollment (Anticipated)
200
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Yunfei Xu, M.D.
- Phone Number: 18560083735
- Email: xuyunfei1988@126.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients with Biliary Tract Carcinoma
Description
Inclusion Criteria:
- Age ≥18, male or female;
- Patients with histologically or cytologically confirmed unresectable or metastatic BTC, including intrahepatic cholangiocarcinoma (IHCC), extrahepatic cholangiocarcinoma (EHCC), and gallbladder cancer (GBC); Surgical resection with positive margins are allowed;
- ECOG score 0-2;
- Expected survival of ≥12 weeks;
- Confirmed measurable (or evaluable) lesions that meet the requirements of RECIST 1.1;
It is not less than 7 days since the end of the last systematic treatment, and the palliative treatment of the limited area is allowed
Treatment has been over 4 weeks;
- The function of major organs and bone marrow was basically normal;
- Fully understand this study, voluntarily participate in it, and sign the informed consent.
- Fertile male or female patients shall volunteer to use effective contraceptive methods, such as double barrier contraception, condoms, oral or injected contraceptives, and intrauterine devices, during the study period and within 90 days after the last dosing of the investigational drug. All-female patients will be considered fertile unless they have had natural menopause, or artificial menopause, or sterilization (such as hysterectomy, bilateral adnexectomy, or ovarian radiation)
Exclusion Criteria:
- Fine basal skin that has been diagnosed with other malignant tumors within the past 5 years and has been effectively treated (Except for cell carcinoma, squamous cell carcinoma of the skin, or in situ cervical cancer and breast cancer after effective resection outside);
- Receiving other investigational drugs or approved or under development antitumor therapies;
- Patients with contraindications to Surufatinib (e.g., active bleeding, ulcers, intestinal perforation, bowel)Obstruction, medically uncontrolled hypertension, grade III-IV cardiac dysfunction, major surgery within 30 days, severe liver and kidney insufficiency, etc.);
- The patient has any current disease or condition that affects the absorption of the drug, or the patient cannot take it orally Surufatinib;
- Demonstrated allergy to any component of the test drug and/or its excipients;
- Pregnant (positive pregnancy test before dosing) or breast-feeding women;
- Patients with large pleural effusion or ascites requiring drainage;
- Taken a drug containing hyperforin perforatum within 3 weeks prior to the first study, or before taken other CYP3A4 strong inducer or inhibitor within 2 weeks;
- The investigator determined that liver metastases accounted for 50% or more of the total volume of the liver;
- Clinically intervened biliary obstruction was not in remission or required anti-infective therapy as determined by the investigator 14 days prior to the first study drug treatment;
- Previous liver transplantation;
- Clinically significant electrolyte abnormalities as determined by the investigator;
- Any other diseases with clinically significant metabolic abnormalities, abnormal physical observations, or abnormal laboratory findings, which are judged by the investigator as evidence that the patient has a disease or condition that is unsuitable for the study drug (e.g., epileptic seizures requiring treatment), or that would interfere with the interpretation of the study results, or that may put the patient at high risk.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Surufatinib
Patients with BTC visited the site from 2021 to 2023 and received Surufatinib therapy.
|
The study is a real-world study.
According to the actual medical history of patients, the usage of Surufatinib was collected.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival (PFS)
Time Frame: 6 months after the last patient enrolled
|
PFS was defined as the length of time from the administration of the first-dose until disease progression or death from any cause before disease progression.
|
6 months after the last patient enrolled
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safty
Time Frame: up to 4 weeks after the last dose
|
The rate of AE and SAE in patients with BTC receiving surufatinib,AEs/SAEs were evaluated using NCI-CTCAE v5.0
|
up to 4 weeks after the last dose
|
Disease Control Rate(DCR)
Time Frame: 6 months after the last patient enrolled
|
DCR was defined as the percentage of patients with complete response (CR), partial response (PR) and stable disease (SD) according to Response Evaluation Criteria in Solid Tumours (RECIST).
|
6 months after the last patient enrolled
|
Overall survival (OS)
Time Frame: 6 months after the last patient enrolled
|
OS was defined as the length of time from the administration of the first-dose until death from any cause. or lost of follow-up |
6 months after the last patient enrolled
|
Objective Response Rate (ORR)
Time Frame: 6 months after the last patient enrolled
|
ORR was defined as the percentage of patients with complete response (CR) and partial response (PR) according to Response Evaluation Criteria in Solid Tumours (RECIST).
|
6 months after the last patient enrolled
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
QoL
Time Frame: 6 months after the last patient enrolled
|
Using quality of life questionnaire (EORTC QLQ-C30) to collect the score.
Scale range is 30~126, higher values are considered to be a better outcome.
|
6 months after the last patient enrolled
|
Biomarkers
Time Frame: before the first dose
|
Explore the correlation between curative effect and different biomarkers, such as EGFR mutation, FGFR etc.
|
before the first dose
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
September 20, 2021
Primary Completion (Anticipated)
December 20, 2022
Study Completion (Anticipated)
December 20, 2023
Study Registration Dates
First Submitted
September 21, 2021
First Submitted That Met QC Criteria
September 22, 2021
First Posted (Actual)
October 1, 2021
Study Record Updates
Last Update Posted (Actual)
October 1, 2021
Last Update Submitted That Met QC Criteria
September 22, 2021
Last Verified
September 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HMPL-012-RWS-BTC101
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Biliary Tract Carcinoma
-
Brno University HospitalRecruitingBiliary Tract Carcinoma | Biliary ObstructionCzechia
-
The First Affiliated Hospital with Nanjing Medical...Recruiting
-
Fudan UniversityRecruitingBiliary Tract CarcinomaChina
-
Fudan UniversityActive, not recruitingBiliary Tract Carcinoma | Initially UnresectableChina
-
AstraZenecaRecruitingHepatocellular Carcinoma | Biliary Tract CancerChina, Spain, Korea, Republic of, Italy, United Kingdom, United States, Japan, Taiwan, Hong Kong
-
Krankenhaus NordwestGerman Research FoundationRecruitingBiliary Tract Cancer | Incidental Gallbladder CarcinomaGermany
-
Massachusetts General HospitalAstraZenecaRecruitingHepatocellular Carcinoma | Biliary Tract CancerUnited States
-
Tongji HospitalRecruitingHepatocellular Carcinoma | Biliary Tract CancerChina
-
Asan Medical CenterRecruitingHepatocellular Carcinoma | Biliary Tract CancerKorea, Republic of
-
University Health Network, TorontoActive, not recruitingGallbladder Carcinoma | Biliary Tract CarcinomaCanada
Clinical Trials on Surufatinib
-
The Affiliated Hospital of Xuzhou Medical UniversityRecruiting
-
Qilu Hospital of Shandong UniversityThe Affiliated Hospital of Qingdao University; Shandong Provincial Hospital... and other collaboratorsNot yet recruitingNeuroendocrine Tumor Grade 3
-
Hutchison Medipharma LimitedCompletedHealthyUnited States
-
Zhejiang Cancer HospitalRecruitingBile Duct AdenocarcinomaChina
-
Shanghai Ninth People's Hospital Affiliated to...RecruitingHead and Neck Cancers - Salivary GlandChina
-
Changhai HospitalNot yet recruitingPancreatic Neuroendocrine TumorChina
-
Fudan UniversityNot yet recruitingSoft Tissue Sarcoma Adult
-
Fudan UniversityRecruitingDifferentiated Thyroid CancerChina
-
HutchmedNo longer available
-
Sun Yat-sen UniversityRecruiting